Acrivon Therapeutics downgraded to Hold from Buy by JonesResearch, awaiting more data

From Yahoo Finance: 2025-05-17 12:30:00

JonesResearch downgraded Acrivon Therapeutics (ACRV) to Hold from Buy without a price target. Investors may focus on ACR-2316 to re-validate the tumor-selection platform. The firm prefers to wait for initial data in the second half of 2025 and more meaningful data in 2026 before recommending the shares. Jones wants to see “real de-risking clinical data” to value Acrivon’s platform.

For more financial news, visit TheFly for real-time updates and market-moving information.

Check out top stocks recommended by analysts for investment opportunities.

Get more information on ACRV, including disclaimer and disclosure details.

Read more: Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch